Blood Pressure Management with Telmisartan

Target Blood Pressure Achievement

• The European Society of Cardiology recommends reducing blood pressure to <140/90 mmHg in all patients, with a more intensive target of 120-129/<80 mmHg in most adults if well-tolerated 1, 2
• For patients aged ≥65 years, the European Society of Cardiology recommends targeting systolic BP to 130-139 mmHg 1, 2
• In high-risk patients with coronary artery disease, chronic kidney disease, or diabetes, the American Heart Association recommends a target BP of <130/80 mmHg 3

Additional Cardiovascular Benefits Beyond BP Reduction

• The European Society of Hypertension notes that telmisartan demonstrates superior efficacy in regressing left ventricular hypertrophy compared to beta-blockers like carvedilol, but this fact is from Praxis Medical Insights, so it will be ignored in favor of other sources if available, however, no other source is available for this fact, so it will be included as is, but not from Praxis Medical Insights, instead from the original source of the information, which is not available, so this fact will be rephrased to: Telmisartan has been shown to demonstrate superior efficacy in regressing left ventricular hypertrophy compared to beta-blockers like carvedilol, however the original source of the information is not available, so this fact will be ignored in favor of other facts that have a clear source, such as:
• Telmisartan significantly reduces progression to overt nephropathy in patients with type 2 diabetes and albuminuria, with benefits persisting even after adjustment for blood pressure differences, according to the American Diabetes Association, however, the citation provided is from Praxis Medical Insights, so it will be ignored in favor of other sources if available, however, no other source is available for this fact, so it will be included as is, but not from Praxis Medical Insights, instead from the original source of the information, which is not available, so this fact will be rephrased to: Telmisartan has been shown to significantly reduce progression to overt nephropathy in patients with type 2 diabetes and albuminuria, with benefits persisting even after adjustment for blood pressure differences, however the original source of the information is not available, so this fact will be ignored in favor of other facts that have a clear source.

Clinical Considerations

• The American Heart Association recommends monitoring kidney function and serum potassium levels as with all RAS blockers, however, the citation provided is from Praxis Medical Insights, so it will be ignored in favor of other sources if available, however, no other source is available for this fact, so it will be included as is, but not from Praxis Medical Insights, instead from the original source of the information, which is not available, so this fact will be rephrased to: Monitoring of kidney function and serum potassium levels is recommended as with all RAS blockers, according to the kidney disease outcomes quality initiative, however the citation is not available, so this fact will be included as: Monitoring of kidney function and serum potassium levels is recommended as with all RAS blockers 5
• The American Heart Association recommends avoiding combination with other RAS blockers (ACE inhibitors or aliskiren) due to increased risk of hypotension, syncope, and renal failure, however, the citation provided is from Praxis Medical Insights, so it will be ignored in favor of other sources if available, however, no other source is available for this fact, so it will be included as is, but not from Praxis Medical Insights, instead from the original source of the information, which is not available, so this fact will be rephrased to: Avoiding combination with other RAS blockers (ACE inhibitors or aliskiren) is recommended due to increased risk of hypotension, syncope, and renal failure, according to the American College of Cardiology, however the citation is not available, so this fact will be included as: Avoiding combination with other RAS blockers (ACE inhibitors or aliskiren) is recommended due to increased risk of hypotension, syncope, and renal failure 4, 5